Navigation Links
Tumors with ALK rearrangements can harbor more mutations
Date:4/22/2013

DENVER The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung adenocarcinoma cases harbor KRAS mutation, EGFR mutation, or ALK translocation, and an additional 5 percent or so have been shown to have mutations involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, and AKT. In the vast majority, these driver mutations are mutually exclusive. But in a recent study published in the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology (JTO) researchers have found that tumors with ALK rearrangements can harbor additional mutations.

Researchers looked at 25 cases of pulmonary adenocarcinoma surgically treated at Mayo Clinic between 1999 and 2007 with ALK gene rearrangement, confirmed by break-apart fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC). Using the DNA extracted from formalin-fixed paraffin-embedded tumor samples, a MassArray-based Lung Cancer Mutations Screening Panel was performed to test for 179 individual mutations in 10 genes, with positive results confirmed by sequencing.

They found additional mutations in 5 of 25 (20 percent) of ALK positive cases. Four of these were point mutation in the MET gene that are of unknown clinical significance, since they may represent germline polymorphisms. However, one case had an EGFR mutation, further supporting that EGFR mutations can be present in ALK rearranged tumors, although it is rare.

"Much is yet to be learned about treatment of patients with both ALK rearrangement and EGFR mutation," the authors report. "Although some of these patients have had a good response to the EGFR inhibitors erlotinib and gefitinib, one patient reportedly showed resistance to erlotinib. Further research is needed to determine if patients with coexisting EGFR mutation and ALK gene rearrangement may have altered response to EGFR or ALK inhibitors. This will be important to determine whether these drugs should be used in a synchronous or sequential fashion to achieve maximum benefit."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Wayne State researchers seek calcium channels to target cancer tumors
2. Hundreds of alterations and potential drug targets to starve tumors identified
3. Hundreds of alterations and potential drug targets to starve cancer tumors identified
4. Chemical shift MRI helps differentiate renal cell tumors more likely to metastasize
5. Virus-like particles provide vital clues about brain tumors
6. Freezing Treatment May Help Destroy Lung Tumors: Study
7. Electrical pulse treatment pokes holes in hard-to-treat tumors
8. AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
9. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
10. Different drug combinations work best for prevention versus treatment of colorectal tumors
11. Engineered T cells kill tumors but spare normal tissue in an animal model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... Dickinson Insurance & ... by announcing a new fundraiser in support of a local boy named Barrett, who ... campaign will bring awareness to, and rally support for, all local families dealing with ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical ... in the heart of Old Town at 108 South Columbus St, Suite 201, Alexandria, ... highest level of medical care in the convenience of their homes, offices or at ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its ... on February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This ... to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party ...
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company ... announced today that the Company will present its operational ... Tuesday, February 16, 2016, at 4:30 p.m. ET.  The ... of its business and growth strategy, as well as ... 2015. --> --> ...
(Date:2/11/2016)... Colo. , Feb. 11, 2016  Ampio Pharmaceuticals, ... 10, 2016, it entered into a Controlled Equity Offering ... ("Cantor Fitzgerald"). Michael Macaluso , Chairman and ... stated that we are not currently raising money and ... 2016 and into 2017 and still complete all of ...
(Date:2/11/2016)... February 11, 2016 North America ... published by MarketsandMarkets, The global market is expected to reach USD ... at a CAGR of 10.2%. --> North America ... 2020", published by MarketsandMarkets, The global market is expected to reach ... growing at a CAGR of 10.2%. --> According to ...
Breaking Medicine Technology: